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ABSTRACT: Retinoids, such as all-trans-retinoic acid (ATRA),
are endogenous signaling molecules derived from vitamin A that
influence a variety of cellular processes through mediation of
transcription events in the cell nucleus. Because of these wide-
ranging and powerful biological activities, retinoids have
emerged as therapeutic candidates of enormous potential.
However, their use has been limited, to date, due to a lack of
understanding of the complex and intricate signaling pathways
that they control. We have designed and synthesized a family of
synthetic retinoids that exhibit strong, intrinsic, solvatochro-
matic fluorescence as multifunctional tools to interrogate these
important biological activities. We utilized the unique photo-
physical characteristics of these fluorescent retinoids to develop
a novel in vitro fluorometric binding assay to characterize and
quantify their binding to their cellular targets, including cellular retinoid binding protein II (CRABPII). The dihydroquinoline
retinoid, DC360, exhibited particularly strong binding (Kd = 34.0 ± 2.5 nM), and we further used X-ray crystallography to
determine the structure of the DC360−CRABPII complex to 1.8 Å, which showed that DC360 occupies the known
hydrophobic retinoid binding pocket. Finally, we used confocal fluorescence microscopy to image the cellular behavior of the
compounds in cultured human epithelial cells, highlighting a fascinating nuclear localization, and used RNA sequencing to
confirm that the compounds regulate cellular processes similar to those of ATRA. We anticipate that the unique properties of
these fluorescent retinoids can now be used to cast new light on the vital and highly complex retinoid signaling pathway.
Retinoids, such as all-trans-retinoic acid (ATRA) (Figure1), make up a class of endogenous small molecules
derived from or functionally related to vitamin A.1 These
compounds exert a significant influence on a wide range of
cellular processes in chordates, including differentiation,
proliferation, apoptosis, and homeostasis, by regulating tran-
scriptional control in the cell nucleus.2 To carry out this
function, retinoids are high-affinity ligands for a family of
nuclear receptor proteins known as the retinoic acid receptors
(RARs) and retinoid X receptors (RXRs).3−5 Once they are
bound to these receptors, dimerization allows the formation of
nuclear receptor heterodimers (RAR/RXR), which function as
stable platforms for interactions with short DNA sequences
termed retinoic acid response elements (RAREs).6,7 These
interactions facilitate transcriptional regulation of retinoic acid
signaling pathways.8
As a result of the central role of retinoids in differentiation,
endogenous retinoids have been used as potent therapeutics
for the treatment of cancers and skin conditions2,3,9,10 and as
key reagents for stem cell biology.11,12 However, despite the
potential of retinoids for widespread therapeutic use, this
potential has yet to be realized except in very limited
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contexts.3,10 The main reason for this is our lack of
understanding of the temporal nature of retinoid signaling
and the way in which the activation of different RAR types
controls signaling pathways with respect to temporal- and cell-
specific pathways of transcriptional regulation. Furthermore, it
has become increasingly apparent that retinoids also act in a
“nongenomic” manner, through the regulation of kinase
phosphorylation and mRNA stability.2,13 These additional
biochemical activities add further layers of complexity to
retinoid signaling pathways.
Clearly, more work is needed to fully understand the diverse
biological activities of these compounds and the signaling
pathway(s) that they govern. However, ATRA and its
endogenous isomers are highly susceptible to photoisomeriza-
tion and degradation under typical laboratory lighting because
of their conjugated polyene structure and exhibit poor
chemical stability in general, meaning that the use of these
compounds as routine reagents carries an inherent uncertainty
and unreliability.14,15 Therefore, new compounds, probes,
tools, and techniques are required to understand this complex
biological pathway that has immense therapeutic potential.
In previous work, we developed a synthetic diphenylacety-
lene analogue of ATRA, known as EC23 (Figure 1),14 which
exhibits excellent photostability and biological activity
comparable to that of ATRA in cellular differentiation assays.
As a result, EC23 is now used as a potent and more reliable
surrogate for ATRA in a number of laboratories.11,16−18 During
development of EC23, we noticed that the compound
exhibited fluorescence when excited with ultraviolet (UV)
light and were intrigued by the possibility of conducting
imaging studies to test the correlation between cellular
localization and biological activity. However, because EC23
requires excitation at wavelengths (λmax = 300−310 nm) that
are damaging to cells, attempting to image EC23 would not be
possible without affecting the underlying cell biology.19 ATRA
is also fluorescent under UV excitation; however, this is a much
weaker effect, and excitation also initiates rapid photo-
isomerization, causing significant changes to the biological
activity of the compound.14,20−22 Fluorescence imaging using
these retinoids would, therefore, be unwise.
We anticipated that the incorporation of a strong π-donor
moiety (e.g., -NH2 or -NR2) into the existing diphenylacety-
lene structure of EC23 would result in significant bath-
ochromic shifts in absorption and emission, ideally allowing
imaging using typical microscope excitation sources, e.g., 405
nm.23−29 Therefore, if the 1,1,4,4-tetramethyl-1,2,3,4-tetrahy-
dronaphthalene (TTN) group of EC23 were substituted for an
analogous, lipophilic, π-donating tetrahydroquinoline (THQ)
or dihydroquinoline (DHQ) (Figure 1), then the resultant aza-
retinoid would exhibit improved fluorescence properties. This
would enable cellular imaging and other biochemical and
biophysical studies without external staining or fluorophore
tagging and, most importantly, without affecting the underlying
biology. In fact, examples of fluorescence imaging of bioactive
compounds without the tagging of a fluorophore, which is
likely to interfere with biological activity, are relatively rare in
the literature.30
Therefore, we report herein the synthesis, photophysical
properties, binding characteristics, cellular imaging, and initial
biological characterization of a library of synthetic retinoids
that exhibit strong, intrinsic, solvatochromatic fluorescence.
■ RESULTS AND DISCUSSION
Design and Synthesis. Starting with highly lipophilic,
electron-rich tetrahydroquinolines (THQ) and dihydroquino-
lines (DHQ),31,32 we designed a convergent synthesis strategy
(Figure 2A) in which a range of these donor structures (1a−f)
were coupled using the Sonogashira or Suzuki−Miyaura
methodology, either as the iodide or as the corresponding
boronic ester, with a series of conjugated acceptors (2a−e) to
give retinoid esters 3a−i (Figure 2B). The esters were then
saponified using aqueous NaOH in tetrahydrofuran (THF) to
give the desired retinoid structures (4a−i, DCXXX) (full
synthesis routes and procedures are shown in the Supporting
Information).33 The majority (4a−g) were structurally related
to EC23, a potent RAR agonist,16,34 but two other compounds,
DC375 (4h) and DC479 (4i), were related to the RARβ/
RARγ agonist, TTNN.34 X-ray crystal structures of DC271
(4c) (previously reported as an RAR agonist35) and DC360
(4g) are shown in the Supporting Information, highlighting
their planar structures.
In previous work, we found that synthetic retinoids that are
“too long” or “too short”, compared to ATRA, exhibit vastly
reduced biological activities in TERA2.cl.SP12 human
embryonal carcinoma stem cells.28 To ascertain if these
observed differences were due to differences in cellular
localization or poor binding affinity for the RARs, or both,
we prepared fluorescent, biologically inactive retinoids by
simply shortening or lengthening the acceptor structure.
Longer retinoids, DC32436 (4j) and DC329 (4k), were
prepared by attaching cinnamic (2e) and naphthoic acid (2c)
acceptor structures, respectively, and a shorter retinoid, DC461
(4l), was synthesized by addition of a simple benzoic acid (2f)
moiety (Figure 2B).
Photophysical Characterization. Each compound ex-
hibited two strong absorption bands in the UV and near-violet
ranges due to the ability to access intramolecular charge
transfer (ICT) excited states.23,24 As a result, the compounds
exhibited solvatochromatic absorption characteristics (Figure 3
and Table S2), with a bathochromic shift in the absorbance
band evident in nonpolar solvents (toluene) compared to polar
solvents [EtOH and dimethyl sulfoxide (DMSO)]. Further-
more, the compounds also displayed highly solvatochromatic
fluorescence emission due to efficient charge transfer from the
donor THQ/DHQ structure to the acceptor carboxyl moiety,
with a significant bathochromic shift observed in polar solvents
(Figure 3 and Table S1). In comparison to EC23 (see Table
Figure 1. Comparison of endogenous retinoid, ATRA,2,10 synthetic
retinoid EC23,14 and design of a fluorescent retinoid.
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S1), each of the compounds exhibited significant bathochromic
shifts in absorption and emission in all solvents, as originally
anticipated. The longer compounds, DC32436 (4j) and DC329
(4k), exhibited a further bathochromic shift, by virtue of the
increased charge separation between the donor and acceptor
moiety. Equally, the shorter DC461 (4l) exhibited a
hypsochromic shift compared to the other compounds due
to decreased charge separation.
It was noted that, for all of the compounds, the fluorescence
emission in aqueous solutions was severely quenched (see
Table S3), presumably due to aggregation effects caused by the
high lipophilicity of the compounds. This was in stark contrast
to the high quantum yields and hypsochromically shifted
emission observed in toluene. We anticipated that this
behavior would be particularly useful in cellular imaging and
biophysical studies, by providing environmental information in
addition to localization.
Retinoid Protein Binding. We next sought to assess the
ability of the compounds to bind to a retinoid binding protein,
and it was anticipated that the unique fluorescence properties
of the fluorescent retinoids could be utilized to directly
monitor binding to a ligand binding pocket. For these proof-of-
principle experiments, we chose cellular retinoic acid binding
protein II (CRABPII), a low-molecular weight (15.94 kDa),
easily expressed, retinoid shuttling protein that is responsible
for the translocation of retinoids from the cytoplasm to the
nucleus and for transfer of retinoids to the RARs.37−39
Figure 2. (A) Synthetic strategy for the assembly of a library of fluorescent retinoids involving cross coupling of donors 1 and acceptors 2 to
provide esters 3. Subsequent saponification provided fluorescent retinoids 4. (B) Chemical structures of fluorescent retinoids, 4a−i, and lengthened
and/or shortened compounds, 4j−l, designed to be non-retinoid in activity.
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GST-CRABPII was produced via recombinant expression in
Escherichia coli (BL21 DE3), before carrying out purification
based on affinity for glutathione-sepharose.37 The purity was
assessed by sodium dodecyl sulfate−polyacrylamide gel
electrophoresis and confirmed by mass spectrometry before
the determination of concentration by absorption measure-
ments at 280 nm. We then conducted an initial fluorometric
binding study using DC360 (4g). A titration approach was
used in which CRABPII was gradually titrated into a
phosphate-buffered saline solution of the retinoid (50 nM)
in a quartz cuvette, and the fluorescence signal was then
measured after the system had equilibrated. As Figure 4A
shows, at 0 nM CRABPII, the fluorescence signal from the
compound was heavily quenched and not detectable. However,
as CRABPII was added, a significant increase in fluorescence
intensity was observed. At higher concentrations ([CRABPII]
> 100 nM), the increase in fluorescence intensity plateaued,
and no further increase was evident. The observed emission
wavelength in this experiment was similar to that in toluene,
suggesting that the compound was localized in a nonpolar
environment.40,41 Furthermore, the observation that the
increase in emission intensity was particularly large and that
this increase plateaued suggested that DC360 (4g) binds to the
insulated, hydrophobic retinoid binding site of CRABPII,
where it is no longer quenched by neighboring molecules, and
exhibits a saturable binding.
To determine the strength of this binding interaction, we
conducted the fluorometric titration experiment in duplicate
and recorded the emission intensity at 460 nm with excitation
of DC360 (4g) at 340 nm as the CRABPII concentration was
increased. The values of emission intensity at 460 nm were
then processed, taking dilution and the minor contribution in
fluorescence signal from CRABPII and the solvent into
account. The processed emission intensity values were then
plotted against the CRABPII concentration to give a binding
isotherm (Figure 4B).
To quantify the strength of interaction, nonlinear regression
analysis was performed to determine the dissociation binding
constant, Kd, of the interaction between DC360 (4g) and
CRABPII. We employed the Hill equation,42 using GraphPad
Prism 7.0d, and determined the Kd of the interaction between
DC360 and CRABPII to be 34.0 ± 2.5 nM, a value similar to
that determined in the literature for ATRA (Kd = 14.2 nM).
37
This confirmed that DC360 (4g) bound to CRABPII with a
high affinity and indicated that the hypsochromically shifted
emission wavelength and high intensity were due to the
compound binding to the insulated retinoid binding pocket.
The binding affinities of the other fluorescent retinoids were
then assessed using the same approach. As Table 1 shows, all
of those compounds designed to be active retinoids (4a−i)
were excellent CRABPII ligands with submicromolar binding
affinities. It was further clear that the different R1−R3
substituents caused appreciable changes in the binding
affinities for CRABPII. First, those compounds with R1 =
iPr
(e.g., 4c and 4g) exhibited Kd values lower than the values of
those with smaller R1 groups (4d and 4e). Second, the
increased rigidity of the DHQ of DC360 (4g) appears to
improve the binding affinity compared to that of the
corresponding THQ compound, DC271 (4c). Third, when
the geminal dimethyl group (R2) was removed (DC476, 4g), a
decrease in binding affinity was observed, indicating that this
group is a desirable structural motif for binding to CRABPII.
Finally, when R3 = Me (4a and 4b), a significant improvement
in binding affinity was observed over the corresponding R3 = H
compound, DC440 (4d), suggesting that this ortho methyl
group is also a desirable structural motif.31 The two
compounds derived from known retinoid TTNN (DC375,
Figure 3. Normalized absorption (dashed) and emission (solid)
spectra of DC360 (4g) in a variety of solvents.
Figure 4. (A) Emission spectra of the fluorometric titration of DC360 (4g) (50 nM) with CRABPII in 20 mM K2HPO4, 100 mM KCl buffer (pH
7.4). λex = 340 nm. [CRABPII] = 0−350 nM. (B) Fluorometric titration of DC360 (4g) (50 nM) with CRABPII in 20 mM K2HPO4, 100 mM KCl
buffer (pH 7.4). λex = 340 nm, and λem = 460 nm.
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4h, and DC479, 4i) exhibited similarly strong binding when
compared to that of the corresponding diphenylacetylenes
DC271 (4c) and DC360 (4g).
When the fluorometric binding titrations were conducted
with longer retinoids, DC324 (4j) and DC329 (4k), higher
concentrations of CRABPII were required to saturate the
binding signal. Furthermore, the intensity of the emission from
both was much reduced and the wavelength longer compared
to those of the other fluorescent retinoids (see Figures 14 and
15). These observations first of all showed that both
compounds exhibit reduced binding affinity for CRABPII
but, moreover, indicated that both the intensity and wave-
length of the emission of these compounds can be used to infer
environmental information. Indeed, the weaker and longer
wavelength emission suggests that the compounds are localized
in a more exposed, polar environment rather than the insulated
retinoid binding site of CRABPII. Rather than exhibiting
specific binding, the compounds may be binding nonspecifi-
cally and are therefore simply solvated by CRABPII.
DC461 (4l) also required significantly higher concentrations
of CRABPII to reach saturation according to the fluorescence
binding signal. However, in contrast to the longer compounds,
DC461 exhibited the shorter wavelength, intense, emission
(430 nm) more akin to the those of other fluorescent retinoids
(see Figure S16). This observation indicated that DC461 (4l)
is capable of entering the insulated CRABPII binding pocket
but exhibits much weaker binding affinity, perhaps due to
clashes between the entrance of the pocket (Phe16 and Val77)
and the THQ moiety.40 Thus, the design strategy to
deliberately synthesize shorter or longer fluorescent retinoids
was successful on the basis of the reduced binding affinity for
CRABPII.
To confirm that the modulation of the fluorescence
properties of the fluorescent retinoids upon addition of
CRABPII was due to specific binding, i.e., to the retinoid
binding site, and not simply due to solvation, we crystallized
DC360 (4g) with CRABPII. Crystallization was achieved using
purified CRABPII, incubated with a molar excess of DC360, as
a protein solution in a hanging drop experiment. Crystals were
then cryoprotected, frozen in liquid nitrogen, and dry-shipped
to the Diamond Light Source (beamline I02) for diffraction
experiments. The resulting data were processed using the
CCP4 suite of programs and solved using molecular
replacement from a literature structure (Protein Data Bank
entry 2FR3; further experimental detail given in the Supporting
Information).43 The unbiased Fo − Fc electron density map
clearly showed DC360 (4g) occupying the retinoid binding
site, and the structure (Figure 5A) was then refined to 1.80 Å
(R = 0.17, and Rfree = 0.24).
The compound is anchored inside the pocket (Figure 5B)
via polar interactions between the carboxylate and Arg133/
Tyr135 and by a bifurcated hydrogen bond with Arg112 via a
conserved water molecule (H2O-12) evident in other retinoid
complexes in the literature.41 The DHQ hydrophobic region
forms extensive van der Waals interactions with Leu29 and
Ala33 among other residues on H1 and Val25 and Leu20 on
H2, while Phe16 on H1 forms an offset T-shaped π−π
interaction with the benzoate phenyl moiety. Furthermore,
DC360 (4g) was found to exhibit a binding mode nearly
identical to that of ATRA,40,41 confirming that it can be
characterized as a retinoid. The crystal structure of the
DC360−CRABPII complex also confirmed that the short
wavelength, high-intensity emission of the fluorescent retinoids
observed in the fluorometric titration was due to specific, high-
affinity binding to CRABPII. In light of this, we predicted that
Table 1. Dissociation Constants, Kd, Determined Using the
Hill Equation from Analysis of the Fluorometric Titration
of the Fluorescent Retinoids with CRABPII
fluorescent retinoid Kd (nM) ± standard error
DC122 (4a) 107.3 ± 5.9
DC128 (4b) 68.3 ± 1.8
DC271 (4c) 49.1 ± 2.6
DC440 (4d) 124.8 ± 4.3
DC444 (4e) 94.0 ± 3.7
DC476 (4f) 88.3 ± 2.1
DC360 (4g) 34.0 ± 2.5
DC375 (4h) 62.5 ± 2.6
DC479 (4i) 51.6 ± 3.2
DC324 (4j) ≥875.0 ± 118.4a
DC329 (4k) 132.0 ± 10.1
DC461 (4l) 385.4 ± 28.5
aThe fluorescence signal could not be saturated under the
experimental conditions ([CRABPII] = 0−1500 nM).
Figure 5. (A) CRABPII−DC360 complex with the hydrophobicity surface of the retinoid binding pocket highlighted.44 (B) Key interactions
between DC360 (4g) and the CRABPII binding pocket.
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these compounds were suitable to be shuttled to the cell
nucleus via CRABPII in a cellular context and, therefore,
engage in RAR-mediated gene modulation.
Biological Characterization and Cellular Imaging.
Having established that the majority of the fluorescent
retinoids were excellent ligands for CRABPII, we wanted to
compare the impact of retinoid treatment on gene regulation in
human epithelial cells. To assess this, RNA sequencing was
performed on cells treated with either active retinoids, ATRA,
EC23, and DC271 (4c) or the “overly long” DC324 (4j).
Principal component analysis (PCA) (Figure 6A) showed
that cells treated with EC23 or fluorescent retinoid DC271
(4c) differentially regulated 38−44% of the genes differentially
expressed in response to ATRA. Importantly, retinoid-treated
cell populations were completely distinct from those cells
treated with either DC324 (4j) or DMSO. These data suggest
that DC271 (4c) can be regarded as a retinoid, able to elicit
cellular responses consistent with those of endogenous retinoid
ATRA and synthetic retinoid EC23.14,17 Furthermore, PCA
showed that DC324 (4j) can be regarded as biologically
inactive as a retinoid and that the poor binding affinity for
CRABPII as determined by the in vitro fluorometric binding
titration can be related to downstream biological activity (or
lack thereof).
Figure 6B also summarizes a gene ontology analysis [GO
analysis (see the Supporting Information)] that suggests that
EC23 and DC271 (4c) are better than ATRA at regulating cell
differentiation and related processes, likely to be a result of the
greater stability in vitro of the synthetic retinoids compared to
that of ATRA.11,14,45 Conversely, protective responses to
external agents tend to be upregulated by the synthetic
retinoids but not ATRA, and ATRA, surprisingly for epithelial
cells, upregulates neurogenesis genes in contrast to EC23 or
DC271 (4c) (see Figure S29). This exemplifies the complex-
ities involved in the signaling pathways governed by retinoids
and underlines the need for an improved understanding of
these fascinating behaviors.
The ability to image the localization of a fluorescent retinoid
in human keratinocyte cells (HaCaT) was examined using
confocal microscopy. HaCaTs were treated with 1 μM DC271
(4c) and then imaged after incubation for 72 h, a time period
that has been shown to be required for the regulation of key
Figure 6. (A) Principle component analysis of RNA sequencing data collected from human epithelial cells treated with ATRA, EC23, or fluorescent
retinoid DC271 (4c). (B) Gene ontology (GO) analysis of the number of genes regulated within a regulatory pathway for ATRA, EC23, and
DC271 (4c) represented as a grouped horizontal bar plot (ATRA, DC271, and EC23 as per the legend), with GO regulatory pathways as group
labels.
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differential genes in response to treatment with ATRA and 9-
cis-retinoic acid in these cells.46 The fluorescence emission
from the compound could be detected at around 450−480 nm
when DC271 (4c) was excited with 365−405 nm light (Figure
7). The distribution of the fluorescence signal varied somewhat
depending on compound concentration and the duration of
treatment; however, in general, the compound could be
detected diffusely in the nucleus and in some brightly
fluorescent, punctate structures in the cytoplasm (presumably
lipid vesicles). Given the highly lipophilic structure of DC271
(4c), we were concerned that the compound might localize
nonspecifically in nonpolar, membrane-rich environments such
as mitochondria. However, this was not the case, as we
detected minimal co-labeling of DC271 with the mitochond-
rion-specific dye MitoTracker Red. The nuclear localization
suggests that DC271 (4c) is capable of engaging with the
retinoid protein machinery (including CRABPII) required to
translocate the endogenous retinoid, ATRA, into the nucleus,
the suspected site of RAR-mediated gene regulation.1
Conclusions. In summary, we have demonstrated the
design, synthesis, and characterization of a family of synthetic
retinoids that exhibit strong fluorescence. The solvatochro-
matic behavior of the compounds has been applied in the
development of a novel fluorometric titration assay that
quantified the strength of binding to a retinoid binding protein
involved in retinoid signaling, CRABPII, and could be applied
to any other retinoid binding protein. These experiments
confirmed not only that the majority of the fluorescent
retinoids are excellent ligands for this important carrier protein
but also that this strong binding affinity can be significantly
diminished by increasing or decreasing the length of the
compound. We further showed that the observed modulation
of the fluorescence behavior by CRABPII was due to specific
binding to the retinoid binding site by determining the crystal
structure of CRABPII in complex with DC360 (4g). The
fluorescent retinoids were then applied to a range of cellular
imaging experiments that demonstrated that DC271 (4c) can
be easily imaged in a cellular context, that changes in
localization can be monitored over time, and that the
compounds can be localized to the cell nucleus, the site of
RAR-mediated gene regulation. Finally, we showed that
DC271 (4c) activates the transcription of the same genes
activated by ATRA and EC23 and that a longer fluorescent
compound, DC324 (4j), is an effective non-retinoid,
fluorescent control compound. We now look forward to
applying this multifunctional family of fluorescent retinoids
toward understanding the complex intricacies of retinoid
biological activity, in the hope that the unravelling of these
behaviors can lead to unlocking the immense therapeutic
potential of both endogenous and synthetic retinoids.
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